Xeris Biopharma Holdings, Inc. (XERS) News
Follow Xeris Biopharma Holdings, Inc. (XERS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 24 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
H
Xeris Biopharma Shares Rally on Lifted Guidance, 3Q Beat
By Elias SchisgallShares of Xeris Biopharma rallied after the company lifted its guidance and reported third-quarter results ahead of Wall Street's expectations.The stock was up 21% at $12.68 in Thursday trading. Shares
EQUITY | Nov 05, 2026, 05:51 PM UTC
M
Xeris Biopharma Shares Jump 29% After Q3 Results Top Estimates
Xeris Biopharma shares surged 29% after its third-quarter results topped estimates.
EQUITY | Nov 05, 2026, 03:12 PM UTC
M
Xeris Biopharma Revenue Rises 44%, Raises 2026 Guidance
Xeris reported third-quarter 2026 revenue of $107 million, up 44% year over year. Recorlev net revenue grew 93% to more than $71 million. The company raised its 2026 revenue guidance to $395 million–$405 million and its
EARNINGS | Nov 05, 2026, 02:03 PM UTC
M
Xeris CEO Sees Recorlev Reaching $1B in Annual Sales Earlier Than Expected
CEO John Shannon said Recorlev could generate $1 billion in annual sales three to four years earlier than expected. Xeris shares surged more than 16% in premarket trading Thursday.
EARNINGS | Nov 05, 2026, 01:56 PM UTC
M
Xeris Biopharma Reports Q3 EPS of $0.06
Q3 EPS was $0.06, versus the FactSet estimate of $0.02.
EARNINGS | Nov 05, 2026, 12:45 PM UTC
M
Xeris Biopharma Q3 product revenue beats estimates on Recorlev demand
EQUITY | Nov 05, 2026, 12:27 PM UTC
M
Xeris Biopharma Reports Third-Quarter 2026 Financial Results
Xeris Biopharma reported third-quarter 2026 results. Total revenue increased 44% year over year to $107 million, while Recorlev net revenue increased 93% year over year.
EQUITY | Nov 05, 2026, 12:24 PM UTC
M
Xeris Biopharma Raises 2030 Revenue Outlook to More Than $1B
Xeris Biopharma raised its 2030 revenue outlook to more than $1 billion.
EARNINGS | Nov 05, 2026, 12:11 PM UTC
H
Full Transcript: Xeris Biopharma Holdings Q2 2026 Earnings Call
Xeris Biopharma Holdings (NASDAQ: XERS ) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered APIs. For comprehensive financial da
LIVE | Oct 06, 2026, 10:24 AM UTC
L
Xeris Biopharma Reportedly Draws Takeover Interest — But Firm Says It’s ‘Not For Sale’
Xeris Biopharma (XERS) was in focus on Tuesday after Danish drugmaker Lundbeck reportedly expressed interest in acquiring the Chicago-based biotech firm focused on rare-disease treatments.According to a Bloomberg report
MNA | Sep 29, 2026, 06:01 PM UTC
L
Lundbeck expresses interest in buying Xeris, Bloomberg News reports
Danish drugmaker H Lundbeck A/S has expressed interest in acquiring Xeris Biopharma NASDAQ:XERS, Bloomberg News reported on Tuesday, citing people familiar with the matter.
NEWS | Sep 29, 2026, 05:02 PM UTC
L
Lundbeck Is Said To Express Interest In Buying Xeris Biopharma - Bloomberg News
H Lundbeck A/S OMXCOP:HLUN_A
NEWS | Sep 29, 2026, 04:47 PM UTC
L
XERS: XP-8121 and RECORLEV drive strong growth, targeting major unmet needs and expanding market share
Revenue growth is accelerating, driven by strong performance of three main products and high gross margins. XP-8121 targets a large unmet need in hypothyroidism, with a robust development and commercialization plan. RECO
NEWS | Sep 14, 2026, 06:29 PM UTC
L
XERS’ XP-8121 targets 2030 launch, $1—3B peak sales
XP-8121 is a once-weekly subcutaneous levothyroxine aimed at 3—5 million hypothyroid patients not controlled on oral therapy, with launch targeted for 2030 and peak sales potential of $1—3 billion.
EQUITY | Sep 09, 2026, 04:31 PM UTC
M
XERS XP-8121 targets $1–3B peak sales by 2030 launch
XERS said XP-8121, a once-weekly injectable levothyroxine, aims for $1–3B peak sales, targeting 3–5 million hypothyroid patients inadequately controlled on oral therapy. An FDA-aligned pivotal trial is set to support app
REGULATION | Sep 09, 2026, 03:45 PM UTC
H
XERS XP-8121 enters Phase 3, targeting 2030 FDA approval
XP-8121, a once-weekly injectable levothyroxine, will enter Phase 3 trials by year-end 2026. The program targets FDA approval and launch in 2030, aiming for $1—3B peak net revenue.
REGULATION | Sep 09, 2026, 01:05 PM UTC
L
XERS XP-8121 targets $1-3B hypothyroidism market with 2030 launch
XP-8121 for hypothyroidism is positioned as a once-weekly subcutaneous therapy backed by a clinical program and strong physician interest, with a targeted 2030 launch supported by regulatory alignment and IP.
EQUITY | Sep 09, 2026, 12:51 PM UTC
M
Xeris says XP-8121 Phase 3 on track for late-2028 topline
Xeris Biopharma hosted an XP-8121 program overview, saying Phase 3 Cornerstone is on track to initiate by year-end, with topline results expected in late 2028 and potential U.S. approval and launch in 2030.
REGULATION | Sep 09, 2026, 12:44 PM UTC
L
Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, will host an
EQUITY | Sep 09, 2026, 12:30 PM UTC
L
Xeris outlines XP-8121 program overview webinar details
Xeris said it will provide details for an XP-8121 program overview webinar, according to TradingView News.
EQUITY | Aug 26, 2026, 11:30 AM UTC
L
XERS raises price target to $12 from $9 after NDR takeaways
Hammerstone MarketTalk reports XERS has a raised price target to $12 from $9 following NDR takeaways at BARC, with no additional magnitude or catalyst details provided.
EQUITY | Aug 20, 2026, 11:12 AM UTC
L
Xeris Biopharma Holdings Raises FY2026 Sales Guidance from $380.000M-$390.000M to $385.000M-$390.000M vs $385.229M Est
Xeris Biopharma Holdings (NASDAQ: XERS ) raises FY2026 sales outlook from $380.000 million-$390.000 million to $385.000 million-$390.000 million vs $385.229 million estimate.
EARNINGS | Aug 06, 2026, 11:03 AM UTC
L
Xeris Biopharma Holdings Insider Sold Shares Worth $383,176, According to a Recent SEC Filing
() -- Steven Pieper, CFO, on July 06, 2026, sold 45,000 shares in Xeris Biopharma Holdings (XERS) for $383,176. Following the Form 4 filing with the SEC, Pieper has control over a total of 1,366,053 common shares of the
REGULATION | Jul 07, 2026, 09:19 PM UTC
L
CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Please replace the release issued earlier today with the following corrected version that pro
EQUITY | Jul 03, 2026, 02:40 AM UTC